Author
Verónica Galván
- Indexed works
- 11
- Total citations
- 2,145
- Active years
- 10
Collaborators
Works in the record
PLoS ONE 2010
Open access · CC-BY
Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
Neuroscience 2012
Preprint · OA
Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
Journal of Cerebral Blood Flow & Metabolism 2013
Open access · OA
Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease
American Journal of Physiology-Heart and Circulatory Physiology 2017
Open access · OA
Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment
Aging Cell 2015
Open access · CC-BY
Chronic mTOR inhibition in mice with rapamycin alters T , B , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
Experimental Gerontology 2014
Open access · CC-BY
How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story
Frontiers in Molecular Neuroscience 2014
Open access · CC-BY
Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice
Aging Cell 2019
Open access · CC-BY
mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging
Journal of Neuroscience 2021
Open access · CC-BY
mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease
Gerontology 2018
Open access · OA
A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review
2020
Open access · CC-BY